Mauskopf J, Brodan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2012 Oct;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000
Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Mauskopf JA, Brogan AJ, Smets E, Martin S. Cost-effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients. Poster presented at the 8th International Congress on Drug Therapy in HIV Infection; November 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.